Literature DB >> 11675400

Increased synthesis and avp unresponsiveness of Na,K-ATPase in collecting duct from nephrotic rats.

Georges Deschênes1,2, Sandrine Gonin3, Einath Zolty3, Lydie Cheval2, Martine Rousselot3, Pierre-Yves Martin3, Jean-Marc Verbavatz4, Eric Féraille3, Alain Doucet2.   

Abstract

Renal sodium retention is responsible for ascites and edema in nephrotic syndrome. In puromycin aminonucleoside (PAN)-induced nephrosis, sodium retention originates in part from the collecting duct, and it is associated with increased Na,K-ATPase activity in the cortical collecting duct (CCD). The aims of this study were to evaluate whether the outer medullary collecting duct (OMCD) also participates to sodium retention and to determine the mechanisms responsible for stimulation of Na,K-ATPase in CCD. PAN nephrosis increased Na,K-ATPase activity in the CCD but not in OMCD. The two-fold increase of Na,K-ATPase activity in CCD was associated with two-fold increases in the number of alpha and beta Na,K-ATPase subunits mRNA determined by quantitative RT-PCR and of the total amount of Na,K-ATPase alpha subunits estimated by Western blotting. PAN nephrosis also increased two-fold the amount of Na,K-ATPase alpha subunit at the basolateral membrane of CCD principal cells, as determined by Western blotting after biotinylation and streptavidin precipitation and by immunofluorescence. The intracellular pool of latent Na,K-ATPase units also increased in size and was no longer recruitable by vasopressin and cAMP. This unresponsiveness of the intracellular pool of Na,K-ATPase to vasopressin was not the result of any alteration of the molecular and functional expression of the vasopressin V(2) receptor/adenylyl cyclase (AC) complex. It is concluded that PAN nephrosis (1) does not alter sodium reabsorption in OMCD, (2) is associated with increased synthesis and membrane expression of Na,K-ATPase in the CCD, and (3) alters the normal trafficking of intracellular Na,K-ATPase units to the basolateral membrane.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11675400     DOI: 10.1681/ASN.V12112241

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  7 in total

1.  Sodium transport is modulated by p38 kinase-dependent cross-talk between ENaC and Na,K-ATPase in collecting duct principal cells.

Authors:  Yu-Bao Wang; Valérie Leroy; Arvid B Maunsbach; Alain Doucet; Udo Hasler; Eva Dizin; Thomas Ernandez; Sophie de Seigneux; Pierre-Yves Martin; Eric Féraille
Journal:  J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 10.121

2.  Changes of atrial natriuretic Peptide system in rats with puromycin aminonucleoside-induced nephrotic syndrome.

Authors:  Eun Hui Bae; Jongun Lee; Seong Kwon Ma; Soo Wan Kim
Journal:  Korean J Physiol Pharmacol       Date:  2009-02-28       Impact factor: 2.016

Review 3.  Coordinated Control of ENaC and Na+,K+-ATPase in Renal Collecting Duct.

Authors:  Eric Feraille; Eva Dizin
Journal:  J Am Soc Nephrol       Date:  2016-05-17       Impact factor: 10.121

Review 4.  Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications.

Authors:  Alain Doucet; Guillaume Favre; Georges Deschênes
Journal:  Pediatr Nephrol       Date:  2007-06-07       Impact factor: 3.714

Review 5.  Dysregulation of ENaC in Animal Models of Nephrotic Syndrome and Liver Cirrhosis.

Authors:  Soo Wan Kim
Journal:  Electrolyte Blood Press       Date:  2006-03

Review 6.  Fluid balance concepts in medicine: Principles and practice.

Authors:  Maria-Eleni Roumelioti; Robert H Glew; Zeid J Khitan; Helbert Rondon-Berrios; Christos P Argyropoulos; Deepak Malhotra; Dominic S Raj; Emmanuel I Agaba; Mark Rohrscheib; Glen H Murata; Joseph I Shapiro; Antonios H Tzamaloukas
Journal:  World J Nephrol       Date:  2018-01-06

Review 7.  Nephrotic Syndrome: Oedema Formation and Its Treatment With Diuretics.

Authors:  Sanjana Gupta; Ruth J Pepper; Neil Ashman; Stephen B Walsh
Journal:  Front Physiol       Date:  2019-01-15       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.